23 results about "Chemoradiotherapy" patented technology

The invention discloses a special medical application formula and a preparation method of a selenium-rich ginseng medicinal and edible herbal liquid, and belongs to the technical field of health foods and special medical foods. The formula is prepared from a selenium-enriched ginseng extract, Chinese yam powder, a poria cocos extract, a gordon euryale seed extract, a Chinese date extract, a longan aril extract and auxiliary materials through scientific compatibility, and has the effects of tonifying spleen and kidney, reinforcing qi and nourishing blood aiming at the pathogenesis of spleen and kidney deficiency and deficiency of qi and blood. According to the preparation method, a gradient process combining ultrasonic-assisted ethanol extraction and enzymolysis water extraction is adopted, and active ingredients such as organic selenium, ginseng rare saponin, jujube cAMP and longan polysaccharide are efficiently extracted and reserved. Experiments show that the herbal liquid has a remarkable synergistic effect in the aspects of improving immunity, improving hematopoietic function and resisting fatigue, and is suitable for nutrition support and function conditioning of tumor chemoradiotherapy patients and postoperative weak people.

Aspects of this invention are related to the use of N-desmethyl ruboxistaurin and pharmaceutically acceptable formulations thereof to modulate RSK signaling. Some aspects of the invention relate to the use of N-desmethyl ruboxistaurin to inhibit RSK. Some aspects of the invention provide methods of using N-desmethyl ruboxistaurin in the treatment of subjects with cancer, including breast cancer, ovarian cancer, prostate cancer, lung cancer, hepatocellular carcinoma, colorectal cancer, melanoma, osteosarcoma, myeloproliferative neoplasms, leukemia, and bladder cancer. The disclosed methods extend beyond disease treatment, including supportive care during radiation chemotherapy and prevention of cancer relapse. N-desmethyl ruboxistaurin administration, alone or in combination with other cancer therapies, inhibits RSK and shows a safety profile that supports its long-term use.

The invention belongs to the technical field of biological medicines, and particularly discloses a pH and ultrasound double-response type oncolytic microorganism as well as a preparation method and application thereof. On the basis of a tumor targeting platform, a mild thermal response gene loop expression GM-CSF and a surface-coated oncolytic microbial system are integrated, chemotherapeutic drugs are released in a tumor core area, and immunogenic cell death is induced. A thermal response loop is accurately activated through low-intensity focused ultrasound, and engineering bacteria are promoted to express GM-CSF and secrete a large amount of mannose modified OMVs. Due to the nanometer size and mannose targeting of the OMVs, the OMVs are efficiently enriched in lymph nodes, the OMVs are reprogrammed into an immune activation state from an immune tolerance state, and the OMVs and ICD cooperate to promote dendritic cell maturation, tumor antigen presentation and activation of tumor killer T cells, so that a remarkable and powerful treatment effect is achieved in various tumor models, and the application prospect is wide. A new strategy is provided for remodeling the lymph node immune microenvironment and enhancing the anti-tumor immune response.

The invention relates to the technical field of gene engineering, in particular to SgRNA for targeted knockout of an MINOS1 gene and application of the SgRNA. According to the invention, a CRISPR / Cas9 gene knockout technology is adopted, a LentiCRISPR-V2 vector is constructed by using a CRISPR / Cas9 system, the LentiCRISPR-V2 vector is co-transferred into a porcine small intestine epithelial cell to obtain a positive cell clone, an MINOS1 gene in the positive cell clone is not expressed, the cell death rate under a hypoxia condition can be obviously reduced, and the positive cell clone has hypoxia tolerance. By regulating and controlling MINOS1 expression, the adaptive capacity of an organism to a low-oxygen environment can be enhanced, and a new thought is provided for preventing and relieving altitude stress and improving physiological tolerance in an extreme environment; besides, the hypoxia characteristic of the tumor microenvironment is a key factor causing chemoradiotherapy drug resistance, and the MINOS1 knockout related strategy can reverse the hypoxia tolerance phenotype of tumor cells, so that the sensitivity of the tumor cells to treatment is enhanced, and an innovative direction is provided for overcoming tumor drug resistance.

The invention discloses a traditional Chinese medicine composition for treating middle and advanced stage tumors. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 9-11 parts of ganoderma lucidum slices, 1-3 parts of radix angelicae sinensis, 1-3 parts of cordyceps militaris, 5-7 parts of poria cocos, 1-3 parts of fructus lycii, 2-4 parts of radix astragali, 5-7 parts of polyporus umbellatus, 3-5 parts of ginseng slices and 3-5 parts of exocarpium citri grandis. The traditional Chinese medicine composition has the effects of benefiting qi and nourishing blood, tonifying kidney and spleen, and supporting healthy energy. The traditional Chinese medicine is used for treating qi and blood deficiency syndromes caused by middle and advanced tumors, wherein the syndromes comprise mental exhaustion, limb weakness, body emaciation, pale complexion, inappetence and the like. The traditional Chinese medicine composition can also be used for relieving toxic and side effects after radiotherapy and chemotherapy and early treatment of cancers. The invention further discloses a method for preparing the traditional Chinese medicine composition, the dosage form advantage is remarkable, the preparation process is stable and controllable, and the method is suitable for industrial production.

The invention belongs to the field of biological medicine, and relates to degradable monodisperse embolism microspheres loaded with radionuclides and chemotherapeutic drugs and a preparation method of the degradable monodisperse embolism microspheres. The embolism microspheres are composed of degradable polymer microspheres with negative charges, radionuclides and chemotherapeutic drugs with positive charges. Radionuclides are connected to the degradable polymer microspheres through chemical bonds, and chemotherapeutic drugs with positive charges are loaded on the degradable polymer microspheres through electrostatic adsorption; the embolism microsphere is spherical, the particle size is 20-100 microns, and the variable coefficient of the particle size does not exceed 10%; the base material of the degradable polymer microspheres is formed by photo-initiation polymerization of two different photopolymerization macromolecules. The embolism microsphere provided by the invention can realize in-vivo chemoradiotherapy synergistic treatment, in-vivo development and in-vivo degradability, and has excellent monodispersity at the same time.

Methods for treating solid tumors with anti-PD-L1 and anti-CTLA-4 antibodies concurrently with chemoradiotherapy (cCRT) are disclosed.

The devices, systems, and methods disclosed herein may be directed to a delivery system including a therapeutic member configured for endoluminal placement via the delivery system into the esophagus of the patient, wherein the therapeutic member comprises a treatment portion comprising a film for controlled release of a chemotherapeutic agent. The film may comprise a control region, a therapeutic region, and a substantially impermeable base region. The film is configured to release the chemotherapeutic agent in a direction away from the substantially impermeable base region. The delivery system is configured to enable a treatment provider to position the treatment portion of the therapeutic member proximate to a treatment site associated with the esophagus of the patient, and the therapeutic member is configured to administer a therapeutically effective dose to the treatment site for a sustained period following endoluminal placement of the therapeutic member.

The present invention discloses a method for predicting the risk of esophageal fistula based on clinical data and imaging omics features, which relates to the field of medical artificial intelligence technology. The present invention combines deep learning with traditional imaging omics methods, extracts rich imaging omics features through multiple image processing technologies, and ensures the generalization ability and robustness of the model through a multi-stage feature selection strategy. It develops multiple prediction models based on different feature combinations, including clinical feature models, manually produced imaging omics models, deep learning imaging omics models, clinical-deep learning imaging omics models, and clinical-manually produced imaging omics models. Through cross-validation and model optimization, the efficiency of each model in clinical prediction is ensured, the performance of the models is comprehensively compared, and the prediction model most suitable for clinical application is selected to further improve the accuracy and reliability of the prediction. The present invention improves the accuracy of esophageal fistula risk prediction in esophageal cancer patients after radiotherapy or chemoradiotherapy, provides a strong basis for treatment decision-making for esophageal cancer patients, and has broad clinical application prospects.

The application provides a nano regulator and a preparation method and application thereof. Specifically, water regulation drugs and chemotherapy drugs are co-delivered through metal organic framework nanoparticles or metal polyphenol nanoparticles, the tumor-targeted enrichment and microenvironment-responsive release characteristics of the nano regulator are utilized to release the chemotherapy drugs at the tumor site after cryoablation. The nano regulator can be used for cryoablation sensitization and chemotherapy synergistic treatment, thereby effectively improving the tumor inhibition effect.

The present disclosure relates to methods, combinations and uses for the treatment of cervical cancer using an anti-PD-L1 binding protein or an anti-PD-1 binding protein and chemoradiotherapy.

The invention relates to the technical field of radiotherapy and chemotherapy sensitizers, in particular to application of a preparation with an EMILIN1 gene inhibition effect in preparation of a radiotherapy and chemotherapy sensitizer. Based on deep research on colorectal cancer tumor microenvironment and tumor-related fibroblasts, the invention finds that the expression of EMILIN-1 in radiotherapy and chemotherapy resistant patients is remarkably up-regulated. By designing the siRNA to specifically inhibit the expression of the EMILIN1 gene, the chemoradiotherapy sensitivity of the colorectal cancer can be effectively improved. The invention provides various application forms such as cholesterol-modified siRNA and tumor-associated fibroblasts transfected with siRNA, and the sensitivity of colorectal cancer cells to radioactive rays and chemotherapeutic drugs is remarkably improved. According to the technical scheme, the technical problem that in the prior art, a means capable of effectively inhibiting the chemoradiotherapy resistance phenomenon of the colorectal cancer cells is lacked can be solved, multiple choices are provided for clinical transformation, and good development and application prospects are achieved.

The invention discloses application of an MARCO inhibitor combined with radiotherapy and chemotherapy in treatment of glioma. The invention creatively discovers that the MARCO inhibitor, the radiotherapy and the chemotherapy or the combined use of the MARCO inhibitor, the radiotherapy, the chemotherapy and the PD-1 inhibitor has a remarkable synergistic effect on the glioma for the first time, and the treatment effect of the combined medication mode on the glioma is remarkably superior to that of a single MARCO inhibitor or a chemoradiotherapy strategy. The advantage in treatment of glioma is obvious. The invention provides an effective drug combination strategy for treatment of glioma, and has a good clinical application prospect and important transformation significance in the technical field of research and development of glioma treatment drugs.

The invention discloses an iridium complex, a preparation method thereof and application of the iridium complex in chemoradiotherapy synergistic treatment. In the prior art, the design of systematic'combination of chemoradiotherapy and active targeting 'of iridium complexes and the report of clear mechanism-level evidence (such as gamma-H2AX, cell cycle and the like) are still limited. The invention discloses an iridium complex nano-drug and an application thereof in breast cancer chemoradiotherapy synergistic treatment, the iridium complex nano-drug has high atomic number elements and a targeting molecular nano-material, can enhance radiation energy deposition and enrich tumor tissues, and is a direction for improving radiotherapy sensitivity; the iridium complex has the characteristics of AIE performance, mitochondrial targeting, ROS production and the like, and is expected to be used as a chemotherapy sensitizer and an imaging probe.

The invention relates to a lactylation modified XLF protein, a preparation for inhibiting XLF lactylation and application. The research finds that the function of the XLF in the NHEJ process is adjusted by promoting the interaction between the XLF and Ku80 through protein lactylation. Under the catalysis of GCN5 (lysine acetyltransferase 2A, KAT2A), XLF is lactylated, so that the efficiency of NHEJ is improved, and colorectal cancer (CRC) cells are caused to generate chemotherapy resistance. In addition, inhibition of XLF lactic acidification can increase sensitivity of CRC cells to chemoradiotherapy. A polypeptide is also obtained through design and screening, the polypeptide can specifically inhibit the lactylation of XLF at K288, a synergistic effect is generated on CRC when the polypeptide is combined with 5-FU, and the polypeptide can promote the chemosensitivity of colorectal cancer.

The invention relates to the technical field of medical care informatics, and particularly discloses a remote monitoring system for symptom management of tumor chemoradiotherapy patients, which integrates the functions of patient self-evaluation, automatic grading processing, health propaganda and education and the like at a patient end, and provides the functions of alarm receiving, long-term monitoring, content editing and the like at a medical care end. And remote continuous monitoring and level-to-level management of the symptom data of the radiotherapy and chemotherapy patients are realized in the off-hospital scene. On the basis, a label management system is further arranged and can push personalized propaganda and education contents according to the individual conditions of the patients, an informed agreement module is embedded to improve the information safety of the patients, an interaction module is provided to support doctor-patient feedback communication, and the defect of automatic processing is overcome. According to the remote monitoring system, the monitoring quality is effectively improved, medical resources are saved, the patient compliance is improved, the re-admission rate of 30 days is reduced, and powerful support is provided for precise tumor treatment.

The invention belongs to the technical field of medicines, discloses application of a salvia chinensis active ingredient composition in treatment of esophageal squamous carcinoma, discloses a medication rule for treating ESCC and an action mechanism of a core medicine salvia chinensis, enriches a theoretical system for treating ESCC by traditional Chinese medicine, and provides a new thought and a theoretical basis for subsequent in-depth study on treatment of cancer by traditional Chinese medicine. Compared with traditional radiotherapy and chemotherapy drugs, the salvia chinensis serving as a traditional Chinese medicine has lower toxic and side effects, the active ingredients of the salvia chinensis treat ESCC through a multi-target and multi-channel action mode, the tumor microenvironment can be adjusted more comprehensively, the malignant behavior of tumor cells can be inhibited, the treatment effect can be improved, and the life quality of patients can be improved. Core active ingredients and action targets of salvia chinensis for treating ESCC are defined, important material basis and action targets are provided for developing novel anti-ESCC drugs, the research and development process of related drugs is accelerated, modern development of traditional Chinese medicine is promoted, and new treatment hope is brought to ESCC patients.

The invention provides a composition for treating yin deficiency constipation and a preparation method and application thereof, and belongs to the technical field of pharmaceutical compositions. The composition for treating yin deficiency constipation is prepared from radix rehmanniae recen, radix ophiopogonis, radix glehniae, fructus cannabis, semen pruni, semen boitae, radix astragali, roasted rhizoma atractylodis macrocephalae and fructus perillae. The three monarch drugs synergistically nourish lung yin, stomach yin and kidney yin, yin fluid is supplemented from the source, and the foundation of'water increasing and boat running 'is built; the three ministerial drugs are complementary and synergistic, and lubricate intestinal tracts; astragalus mongholicus and roasted rhizoma atractylodis macrocephalae are used as adjuvant drugs to tonify qi and spleen, prevent the monarch drugs from being sweet, cold, greasy and obstructing stomach, and tonify qi and promote intestinal The traditional Chinese medicine is scientific in compatibility of the medicines, mild in medicine property, capable of giving consideration to both cold and heat and tonifying and reducing, and suitable for old people, postpartum women, weak people after long illness and patients after radiotherapy and chemotherapy.

The invention discloses a nutrition nursing intervention method and device for tumor chemoradiotherapy patients and a medium, and relates to the technical field of medical nursing, and the method comprises the steps: obtaining patient chemoradiotherapy regimen parameters, collecting tumor metabolism data, muscle metabolism data and serum circulating tumor marker concentration, and obtaining a monitoring data set; the monitoring data set comprises toxicity risk factors and radiation dose distribution; the monitoring data set is input into a tumor nutrition competition model to calculate a sweep coefficient, when the sweep coefficient exceeds a pathological threshold value, a deceptive nutrition starting instruction is generated, a composite risk value is calculated based on the toxicity risk factor and radiation dose distribution, and when the composite risk value exceeds a critical threshold value, a double-blocking protocol is triggered, and a decision instruction is generated; blending and applying a liposome injection, an oral controlled release preparation and a functional patch according to the decision instruction to form an integrated intervention composition; according to the method, the optimization of local intervention parameters is realized, and the local mucous membrane repair efficiency is improved.

The invention discloses application of total glucosides of paeony in preparation of a medicine for treating head and neck squamous cell carcinoma, and belongs to the technical field of biological medicine. Aiming at the bottlenecks of high chemoradiotherapy toxicity, low immunotherapy response rate, easy drug resistance of targeted drugs and the like in the existing treatment of head and neck squamous cell carcinoma, the invention provides a preparation method of total glucosides of paeony and a preparation technology of a loaded drug of hydrogel obtained based on modified chitosan. The total glucosides of paeony can inhibit the proliferation rate, the clone forming ability and the in-vitro migration ability of SCC7, FADU and CAL27 head and neck squamous carcinoma cell lines in a dose-dependent manner, and obviously induce cell apoptosis. The multi-target action characteristic of the total glucosides of paeony is utilized, the head and neck squamous cell carcinoma resisting effect is achieved through the ways of adjusting the tumor microenvironment, enhancing immune surveillance and the like, the loaded medicine has good slow release performance and biological safety, a new efficient and low-toxicity strategy is provided for treatment of the head and neck squamous cell carcinoma, and important clinical application value is achieved.

Gene amplifications are an oncogenic driver utilized by many forms of cancer in tumor development or treatment relapse. Promoting genomic instability or the proclivity to propagate genomic alterations through acquired defects in DNA repair machinery, replication licensing, or cell cycle control, gene amplifications not only drive oncogenesis, but also afford an opportunity for therapeutic exploitation. Here, CRISPR-Cas9 nickases are disclosed which selectively promote cancer cell death in a gene amplification-dependent manner. For example, CRISPR- Cas9 nickases generate a lethal number of highly toxic single-ended double-strand breaks within the genome of proliferating cancer cells harboring amplified genomic loci during DNA replication. Cas9 nickases may serve as a tumor-selective therapeutic that mitigates the collateral damage observed with conventional chemoradiotherapies and avoids chemoresistance.

The invention discloses an ultrasonic response type bacterial composite drug-loading system as well as a preparation method and application thereof. The system is formed by taking engineering bacteria as a carrier, grafting chemotherapy prodrug molecules on the surface of the engineering bacteria through atom transfer radical polymerization and then loading a sound-sensitive agent. Compared with the prior art, by optimizing ATRP reaction conditions, efficient grafting of the medicine on the surfaces of bacteria is achieved, and the activity of the bacteria is kept. After intravenous injection, the system is enriched at a tumor site by virtue of a tumor hypoxia targeting carrying drug of attenuated salmonella, and ultrasonic irradiation activates a sound-sensitive agent to generate active oxygen: on one hand, the active oxygen splits a TK bond in a prodrug to release a chemotherapeutic drug, and on the other hand, the active oxygen mediates sonodynamic therapy. The system solves the problems that a traditional drug delivery system is poor in targeting property, uncontrollable in drug release and limited in single treatment effect, and the ATRP technology is mild in preparation process and good in biocompatibility and has wide application prospects in the field of deep tumor targeted therapy.

The invention relates to a polyprotein peptide composition and application of the polyprotein peptide composition in the aspect of hypoproteinemia, and belongs to the field of biological medicine. The polyprotein peptide composition comprises the following components in parts by weight: 40-60 parts of ovalbumin peptide; 15 to 30 parts of fish collagen peptide; 10 to 20 parts of sea cucumber oligopeptide; 5 to 15 parts of cordyceps militaris oligopeptide; and 5 to 15 parts of yeast beta-glucan. The ovalbumin peptide is used as a core protein source, the fish collagen peptide, the sea cucumber oligopeptide, the cordyceps militaris oligopeptide and the yeast beta-glucan are compounded, the components achieve a synergistic effect according to a specific weight ratio, the A / G protein inversion state of a patient suffering from the hypoproteinemia can be rapidly improved, wound granulation tissue hyperplasia and healing are promoted, physical strength is enhanced, fatigue is resisted, and the curative effect is good. The composition can be used for treating hypoproteinemia, enhancing lymphocyte proliferation and NK cell activity, reducing side effects of chemoradiotherapy, improving the curative effect of anti-tumor treatment and remarkably improving the prognosis of patients, and can be widely applied to nutrition intervention, postoperative rehabilitation and tumor chemoradiotherapy adjuvant therapy of hypoproteinemia patients.